Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Beclomethasone Dipropionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.94 |
| ▸ | USP2 | O75604 | 6/20 | 0.94 |
| ▸ | PGR | P06401 | 5/20 | 0.94 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.94 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.94 |
| ▸ | AR | P10275 | 2/20 | 0.94 |
| ▸ | CNR1 | P21554 | 2/20 | 0.94 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.94 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.94 |
| ▸ | MAPT | P10636 | 3/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.76 |
| ▸ | DRD2 | P14416 | 1/20 | 0.76 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | MLNR | O43193 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beclomethasone Dipropionate SCHEMBL14782876 | 0.99 | CYP3A4 (0.95) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL7329 | 0.99 | CYP3A4 (0.95) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL1216647 | 0.98 | CYP3A4 (0.98) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL74650 | 0.98 | CYP3A4 (0.98) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL3930413 | 0.97 | CYP3A4 (0.91) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL6890 | 0.97 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL10392062 | 0.97 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL2404673 | 0.97 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL9768491 | 0.97 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A | |
| Beclomethasone Dipropionate SCHEMBL13653326 | 0.97 | CYP3A4 (1.00) | CYP3A4USP2NR3C1PGRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 972 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401798-A1 | LIPOXIN A4 ANALOGS AND USES THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-12-30 | — | — | US | claimed |
| CN-113795246-A | Injectable sustained release formulation for the treatment of joint pain and inflammation | 福多兹制药公司 | 2021-12-14 | — | — | CN | claimed |
| US-20210177866-A1 | PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-06-17 | — | — | US | claimed |
| US-10966991-B2 | Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-04-06 | — | — | US | claimed |
| US-20200368252-A1 | PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC | CHIESI FARMMACEUTICI S.P.A. (IT) | 2020-11-26 | — | — | US | claimed |
| US-10772896-B2 | Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-09-15 | — | — | US | claimed |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2020-02-04 | — | — | US | claimed |
| US-20180360849-A1 | PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-12-20 | — | — | US | claimed |
| US-10086004-B2 | Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-10-02 | — | — | US | claimed |
| US-20180064666-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2018-03-08 | — | — | US | claimed |
| EP-1073417-A1 | PHARMACEUTICAL AEROSOL FORMULATION | GLAXO GROUP LIMITED (GB) | 2001-02-07 | — | — | EP | claimed |
| US-6149892-A | INHALER HAVING INTERIOR SURFACES COATED WITH BLEND OF FLUOROPOLYMER(S) AND NON-FLUOROPOLYMER(S) AND CONTAINING ACTIVE DRUG AND A FLUOROCARBON PROPELLANT; ACCURATE DRUG DELIVERY | GLAXOWELLCOME, INC. (US) | 2000-11-21 | — | — | US | claimed |
| CN-1048394-C | Medicaments | GLAXO GROUP LTD (GB) | 2000-01-19 | — | — | CN | claimed |
| WO-1999053901-A1 | PHARMACEUTICAL AEROSOL FORMULATION | GLAXO GROUP LIMITED (GB) | 1999-10-28 | — | — | WO | claimed |
| CN-1186473-A | Metered dose inhaler for beclomethasone dipropionate | GLAXO WELLCOME INC (US) | 1998-07-01 | — | — | CN | claimed |
| US-5695744-A | Medicaments | GLAXO GROUP LIMITED (GB) | 1997-12-09 | — | — | US | claimed |
| US-5688782-A | Medicaments for treating respiratory disorders | GLAXO GROUP LIMITED (GB) | 1997-11-18 | — | — | US | claimed |
| EP-0625046-B1 | Pharmaceutical aerosol formulations comprising beclomethasone dipropionate | GLAXO GROUP LTD (GB) | 1997-09-10 | — | — | EP | claimed |
| CN-1078633-A | pharmaceutical preparation | GLAXO GROUP LTD (GB) | 1993-11-24 | — | — | CN | claimed |
| US-4866051-A | TREATMENT OR PROPHYLAXIS OF ASTHMA; INHALANTS | GLAXO GROUP LIMITED (GB) | 1989-09-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401798-A1 | LIPOXIN A4 ANALOGS AND USES THEREOF | LTA4H, ALOX15B, LTB4R | NR3C1 736/4885CYP3A4 423/4885USP2 4225/4885 |
| US-10548864-B2 | Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions | PIN1, RARB, RARA | NR3C1 290/4885CYP3A4 3907/4885USP2 2626/4885 |
| US-20180064666-A1 | ENHANCED ATRA-RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, AUTOIMMUNE DISEASES, AND ADDICTION CONDITIONS | PIN1, RARB, RARA | NR3C1 290/4885CYP3A4 3907/4885USP2 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.